Artiva Biotherapeutics Statistics
Total Valuation
ARTV has a market cap or net worth of $547.08 million. The enterprise value is $207.54 million.
| Market Cap | 547.08M |
| Enterprise Value | 207.54M |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ARTV has 48.89 million shares outstanding. The number of shares has increased by 22.89% in one year.
| Current Share Class | 48.89M |
| Shares Outstanding | 48.89M |
| Shares Change (YoY) | +22.89% |
| Shares Change (QoQ) | +59.71% |
| Owned by Insiders (%) | 4.34% |
| Owned by Institutions (%) | 40.54% |
| Float | 19.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.57 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.16, with a Debt / Equity ratio of 0.03.
| Current Ratio | 24.16 |
| Quick Ratio | 24.06 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.58% and return on invested capital (ROIC) is -23.13%.
| Return on Equity (ROE) | -36.58% |
| Return on Assets (ROA) | -22.34% |
| Return on Invested Capital (ROIC) | -23.13% |
| Return on Capital Employed (ROCE) | -27.16% |
| Weighted Average Cost of Capital (WACC) | 16.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$789,748 |
| Employee Count | 115 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +251.89% in the last 52 weeks. The beta is 2.20, so ARTV's price volatility has been higher than the market average.
| Beta (5Y) | 2.20 |
| 52-Week Price Change | +251.89% |
| 50-Day Moving Average | 10.57 |
| 200-Day Moving Average | 7.41 |
| Relative Strength Index (RSI) | 50.99 |
| Average Volume (20 Days) | 279,352 |
Short Selling Information
The latest short interest is 2.10 million, so 4.29% of the outstanding shares have been sold short.
| Short Interest | 2.10M |
| Short Previous Month | 1.92M |
| Short % of Shares Out | 4.29% |
| Short % of Float | 10.65% |
| Short Ratio (days to cover) | 5.61 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -96.15M |
| Pretax Income | -90.82M |
| Net Income | -90.82M |
| EBITDA | -93.46M |
| EBIT | -96.15M |
| Earnings Per Share (EPS) | -$3.21 |
Balance Sheet
The company has $349.39 million in cash and $9.85 million in debt, with a net cash position of $339.55 million or $6.95 per share.
| Cash & Cash Equivalents | 349.39M |
| Total Debt | 9.85M |
| Net Cash | 339.55M |
| Net Cash Per Share | $6.95 |
| Equity (Book Value) | 347.50M |
| Book Value Per Share | 7.12 |
| Working Capital | 337.70M |
Cash Flow
In the last 12 months, operating cash flow was -$75.23 million and capital expenditures -$1.68 million, giving a free cash flow of -$76.91 million.
| Operating Cash Flow | -75.23M |
| Capital Expenditures | -1.68M |
| Depreciation & Amortization | 2.69M |
| Net Borrowing | -111,000 |
| Free Cash Flow | -76.91M |
| FCF Per Share | -$1.57 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ARTV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.89% |
| Shareholder Yield | n/a |
| Earnings Yield | -16.60% |
| FCF Yield | -14.06% |
Analyst Forecast
The average price target for ARTV is $35.80, which is 219.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.80 |
| Price Target Difference | 219.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |